Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2014
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody
Steffen Ormanns, Volker Heinemann, Mitch Raponi, et al.
BMC Cancer
|
October 22, 2009
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer
Greg M Arndt, Lesley Dossey, Lara M Cullen, et al.
Cell Reports
|
April 19, 2018
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
Hsien-Ming Hu, Xin Zhao, Swati Kaushik, et al.
Cancer Chemotherapy and Pharmacology
|
December 5, 2009
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial
Delphine Rolland, Vincent Ribrag, Corinne Haioun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2018
Exosome-Based Detection of <i>EGFR</i> T790M in Plasma from Non-Small Cell Lung Cancer Patients
Elena Castellanos-Rizaldos, Dominik G Grimm, Vasisht Tadigotla, et al.
Molecular Cancer Research : MCR
|
July 1, 2024
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Katelyn J Noronha, Karlie N Lucas, Sateja Paradkar, et al.
The Journal of Gene Medicine
|
January 19, 2005
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients
Janet L Macpherson, Maureen P Boyd, Allison J Arndt, et al.
Blood
|
December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Mitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Oncotarget
|
January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trial
Elizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2013
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity
Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2014
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody
Steffen Ormanns, Volker Heinemann, Mitch Raponi, et al.
BMC Cancer
|
October 22, 2009
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer
Greg M Arndt, Lesley Dossey, Lara M Cullen, et al.
Cell Reports
|
April 19, 2018
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
Hsien-Ming Hu, Xin Zhao, Swati Kaushik, et al.
Cancer Chemotherapy and Pharmacology
|
December 5, 2009
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial
Delphine Rolland, Vincent Ribrag, Corinne Haioun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2018
Exosome-Based Detection of <i>EGFR</i> T790M in Plasma from Non-Small Cell Lung Cancer Patients
Elena Castellanos-Rizaldos, Dominik G Grimm, Vasisht Tadigotla, et al.
Molecular Cancer Research : MCR
|
July 1, 2024
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Katelyn J Noronha, Karlie N Lucas, Sateja Paradkar, et al.
The Journal of Gene Medicine
|
January 19, 2005
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients
Janet L Macpherson, Maureen P Boyd, Allison J Arndt, et al.
Blood
|
December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Mitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Oncotarget
|
January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trial
Elizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2013
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity
Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, et al.
Page
of 4